AccessBio is a respected technology company that develops and manufactures “ Early diagnosis of the disease in vitro diagnostic technology advanced Based on diagnosis of infectious diseases in the field immediately immunohistochemistry and molecular diagnostic kits diagnostic kits.” Access Bio has supplied products to WHO, MSF, Global Fund and UNICEF for three years from
2008 to 2010 and is selected as a respected technology company for the best products in the world.

Especially, Access Bio has promoted the several reagent’s commercialization such as G69D and diagnosing dengue fever after early Malaria, Aids diagnosis reagents And they are currently developing reagent of diagnosing laryngopharyngitis, influenza.

Stonebridge Capital will take the opportunity of investing in Access Bio’s technology, such as their profitability, market conditions and growth potential insight for a short term.

Stonebridge was able to gain an investment performance of IRR 154.3% and maximize the revenue through Access Bio’s additional growth potential, secure stable revenue structure, and the value of favorable market conditions for more than one year after the IPO.